Ovid Therapeutics Inc. OVID 深 滬
等待開盤 09-05 09:30:00 美东时间
1.29
-0.040
-3.01%
華盛通- 最 高1.34
- 今 開1.28
- 成交量 119.45万股
- 最 低 1.27
- 昨 收 1.33
- 總市值 9173.13万
- 52周最高 1.47
- 市盈率 靜 --
- 換手率 1.68%
- 52周最低 0.2425
- 委 比 74.38%
- 總股本 7110.95万
- 歷史最高 15.89
- 量 比 0.74
- 振 幅 5.26%
- 歷史最低 0.2425
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CAMBIUM NETWORKS PROVIDES COMMERCIAL UPDATE AND UPDATE ON EXECUTIVE OFFICER TRANSITION
HOFFMAN ESTATES, Ill., Aug. 26, 2025 /PRNewswire/ -- Cambium Networks Corporation ("Cambium Networks" or "Cambium") (NASDAQ: CMBM), a leading provider of wireless networking infrastructure s...
08-27 04:32
Ovid Therapeutics Q2 EPS $(0.06) Beats $(0.16) Estimate, Sales $6.272M Beat $76.667K Estimate
Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.16) by 62.96 percent. This is a 150 percent decrease over earnings of $0.12 per share from
08-13 20:13
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
Ovid Therapeutics reported updates on its OV329 Phase 1 study, nearing a Q3 2025 safety and tolerability readout, and OV4071, an oral KCC2 activator, set for Q2 2026 trials. The company signed a $7 million agreement for ganaxolone royalties, strengthening its finances. With $38.3 million in cash, Ovid expects to fund operations into early 2026. Second-quarter 2025 financials showed reduced R&D and G&A expenses compared to 2024, alongside a net lo...
08-13 12:00
Metallus Announces Second-Quarter 2025 Results
Net sales of $304.6 million with net income of $3.7 million and adjusted EBITDA(1) of $26.5 million Operating cash flow of $34.8 million with ending cash and cash equivalents of $190.8 milli...
08-08 04:10
LIONSGATE REPORTS RESULTS FOR FIRST QUARTER FISCAL 2026
Studio Revenue was $556 Million; Net Loss From Continuing Operations Attributable to Shareholders was $94.0 Million or $0.35 Diluted Net Loss Per Share Adjusted Net Loss from Continuing Oper...
08-08 04:05
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference
Ovid Therapeutics Inc. announced that its management will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company, based in New York, focuses on developing small molecule medicines for brain conditions with significant unmet needs. Ovid is advancing a pipeline of novel candidates targeting neuronal hyperexcitability, including OV329 for treatment-resistant seizures and other compounds for CNS disorders. For more ...
07-23 12:30
WESTERN COPPER AND GOLD PROVIDES UPDATE ON ESE SUBMISSION
VANCOUVER, BC, July 15, 2025 /PRNewswire/ - Western Copper and Gold Corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) is pleased to provide an update on its Environmen...
07-15 19:30
GALIANO GOLD PROVIDES NOTICE OF SECOND QUARTER 2025 RESULTS
VANCOUVER, BC, July 8, 2025 /PRNewswire/ - Galiano Gold Inc. ("Galiano" or the "Company") (TSX: GAU) (NYSE American: GAU) is pleased to announce it will release its second quarter ("Q2") 202...
07-08 20:30
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
Ovid Therapeutics ( ($OVID) ) has provided an announcement. On June 23, 2025, O...
06-25 20:49
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Ovid Therapeutics sold its future royalties for ganaxolone outside of China to Immedica Pharma for $7 million. This non-dilutive funding supports Ovid's operations, while Immedica gains control of additional ganaxolone IP rights. Immedica will assume costs related to the licensed IP and expand the license to include more indications. The deal does not affect Ovid's current pipeline.
06-25 12:00
